DIVISLAB - Divi's Lab.
📢 Recent Corporate Announcements
Divi's Laboratories reported a 12% year-on-year increase in total income to ₹2,692 crores for Q3FY26, driven by strong performance in Custom Synthesis and Nutraceuticals. While Profit Before Tax (pre-exceptional) grew to ₹854 crores, the bottom line was impacted by a one-time ₹74 crore exceptional charge related to new government labor codes. The company continues to shift its mix toward Custom Synthesis, which now accounts for 57% of revenue. Management confirmed that GLP-1 pilot and commercial blocks are completed and currently undergoing validation.
- Total income for Q3FY26 rose to ₹2,692 crores from ₹2,401 crores in the previous year.
- Custom Synthesis segment contributed 57% of revenue, while Generics accounted for 43%.
- Material consumption costs improved to 36.3% of sales, down from 39.8% in Q3FY25.
- Exceptional item of ₹74 crores recognized due to revised employee benefit obligations under new labor codes.
- Capital work in progress (CWIP) remains high at ₹2,394 crores, focusing on GLP-1 capacity and Unit 3 expansions.
Divi's Laboratories has officially released the audio recording of its Q3FY26 earnings conference call, which took place on February 11, 2026. The call addressed the company's financial performance for the quarter and the nine-month period ending December 31, 2025. This disclosure is a standard regulatory requirement under SEBI Regulation 30 to ensure all investors have access to management discussions. The recording is now available on the company's investor relations website.
- Earnings call for Q3FY26 and nine months ended Dec 31, 2025, concluded on Feb 11, 2026.
- Audio recording link provided on the company's official website for public access.
- Compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The call was held at 15:00 hrs IST following the quarterly results announcement.
Divi's Laboratories reported a 12.3% YoY growth in consolidated revenue at ₹2,604 crore for Q3 FY26. However, consolidated net profit remained nearly flat at ₹583 crore, compared to ₹589 crore in the previous year, primarily due to a one-time exceptional charge of ₹74 crore related to new Labour Codes. On a sequential basis, revenue and PAT declined by 4.1% and 15.4% respectively. Despite the flat PAT, the 9-month consolidated profit shows a healthy 18.8% growth YoY reaching ₹1,817 crore.
- Consolidated Revenue from operations grew 12.3% YoY to ₹2,604 crore.
- Consolidated Net Profit stood at ₹583 crore, down 1% YoY, impacted by a ₹74 crore exceptional item.
- Profit Before Tax (before exceptional items) increased 17.6% YoY to ₹854 crore.
- Nine-month (9M FY26) consolidated PAT grew 18.8% YoY to ₹1,817 crore.
- Forex gain for the quarter was significantly lower at ₹18 crore compared to ₹64 crore in the previous quarter.
Divi's Laboratories Limited has scheduled its earnings conference call for the quarter and nine months ended December 31, 2025 (Q3FY26) on February 11, 2026. The company will release its unaudited financial results on the same day prior to the call at 15:00 hrs IST. The management will discuss the financial performance and provide updates on business operations. This is a routine regulatory filing in compliance with SEBI Listing Obligations.
- Q3FY26 financial results announcement scheduled for February 11, 2026
- Earnings conference call to be held on February 11, 2026, at 15:00 hrs IST
- Covers financial performance for the quarter and nine months ended December 31, 2025
- Universal dial-in numbers provided are +91 22 6280 1526 and +91 22 7115 8341
Divi's Laboratories has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations for the period ended December 31, 2025. The certificate, issued by KFin Technologies Limited, confirms that all share certificates received for dematerialization were processed and listed on the BSE and NSE. It further verifies that physical certificates were mutilated and cancelled within the required 15-day timeframe. This filing is a standard procedural requirement and indicates no operational irregularities in share handling.
- Compliance certificate submitted for the quarter ended December 31, 2025.
- Confirmation provided by Registrar and Share Transfer Agent, KFin Technologies Limited.
- Securities received for dematerialization were processed and listed on both BSE and NSE.
- Physical certificates were mutilated and cancelled within the mandated 15-day period.
- Name of depositories substituted in the register of members as registered owners.
Divi's Laboratories Limited has announced the closure of its trading window for all designated persons and insiders starting January 1, 2026. This move is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's financial results. The closure pertains to the unaudited financial results for the quarter and nine-month period ending December 31, 2025. The trading window will remain closed until 48 hours after the results are officially declared to the stock exchanges.
- Trading window closure effective from January 01, 2026
- Closure is in anticipation of Q3 and nine-month financial results ending December 31, 2025
- Window to reopen 48 hours after the declaration of financial results
- Board meeting date for result approval to be announced in due course
Financial Performance
Revenue Growth by Segment
Consolidated total income for H1 FY26 rose to INR 5,389 Cr, a 16% increase from INR 4,640 Cr in H1 FY25. In Q2 FY26, the revenue mix shifted significantly toward Custom Synthesis, which now accounts for 56% of revenue (up from ~40% in previous years), while Generics contribute 44%. The Nutraceutical business contributed INR 242 Cr during Q2 FY26. On a constant currency basis, overall revenue growth for Q2 FY26 was 10.79%.
Geographic Revenue Split
Exports account for 90% of total sales revenue as of Q2 FY26. The combined contribution from Europe and the United States stands at 74%. Historically (FY24), Europe accounted for 52.3% of gross sales (up from 40.3% in FY23), while North America decreased to 17.1% (from 28.9% in FY23) due to varying client requirements.
Profitability Margins
Profit After Tax (PAT) for Q2 FY26 was INR 689 Cr, representing a 35% increase compared to INR 510 Cr in Q2 FY25. Profit Before Tax (PBT) stood at INR 912 Cr compared to INR 722 Cr in the previous year's quarter. Net profit margins are driven by a material consumption rate of 39.5% of sales revenue, which has remained consistent with recent trends.
EBITDA Margin
EBITDA margins have historically moved around 40% but have recently stabilized in the 32% to 33% range. Despite the favorable shift in revenue mix toward high-value Custom Synthesis (56% of revenue), margins have not seen a proportional appreciation due to the underlying product mix and the continued 44% contribution from the more competitive Generics segment.
Capital Expenditure
The company is investing in capacity expansion, specifically the operationalization of the Kakinada plant scheduled for the second half of FY25. While specific total INR Cr for future capex is not fully detailed, the company maintains a strong liquidity position with cash and investments of INR 4,229 Cr as of June 30, 2024, to fund these requirements.
Credit Rating & Borrowing
Divi's maintains a CARE AA+; Stable rating for long-term bank facilities (INR 30 Cr and INR 485 Cr) and CARE A1+ for short-term facilities. The company operates with minimal debt, primarily utilizing un-utilized cash credit limits. There are no debt repayment obligations for FY25, indicating a robust capital structure.
Operational Drivers
Raw Materials
Key raw materials are used for the production of Active Pharmaceutical Ingredients (APIs) like Naproxen, Dextromethorphan, and Gabapentin. Material consumption accounts for 39.5% of total sales revenue. Specific chemical names are not disclosed, but they are categorized under API intermediates and nutraceutical ingredients.
Import Sources
Approximately 45% of raw material consumption is met through imports, providing a partial natural hedge against foreign exchange fluctuations. Specific sourcing countries are not named, but the company maintains a global supply chain to support its 90% export-oriented revenue model.
Capacity Expansion
Divi's is increasing overall capacity with the operationalization of the Kakinada plant in H2 FY25. The company utilizes multi-purpose manufacturing facilities to allow flexibility between generic API production and custom synthesis projects.
Raw Material Costs
Raw material costs (material consumption) represent 39.5% of sales revenue. The company manages these costs through a natural hedge, as 45% of materials are imported while 90% of revenue is exported, mitigating the impact of currency volatility on the cost structure.
Manufacturing Efficiency
Efficiency is driven by running plants at 'full stream' for large-volume products and then stocking them. This strategy optimizes the use of multi-purpose plants for complex custom synthesis projects, which now comprise 56% of the revenue mix.
Strategic Growth
Expected Growth Rate
10-15%
Growth Strategy
Growth is targeted through a 10-15% consistent revenue increase by diversifying revenue concentration (aiming to reduce top 5 product concentration to <30%), operationalizing the Kakinada plant in H2 FY25, and leveraging strong R&D capabilities to increase the share of the Custom Synthesis segment, which has already grown to 56% of the mix.
Products & Services
Active Pharmaceutical Ingredients (APIs) including Naproxen, Dextromethorphan, and Gabapentin; Intermediates; and Nutraceutical ingredients. Services include Contract Research and Manufacturing Services (CRAMS) and Custom Synthesis for global innovator pharma companies.
Brand Portfolio
Divi's Laboratories (USA) Inc. and Divi's Laboratories Europe AG (subsidiaries).
New Products/Services
The company is continuously adding to its Custom Synthesis portfolio, which saw its 'best ever' revenue performance in Q2 FY26. Specific new product names are often protected by confidentiality agreements with innovators.
Market Expansion
Expansion is focused on increasing the utilization of the Kakinada plant and deepening relationships with top global pharmaceutical companies in regulated markets (US and Europe).
Market Share & Ranking
Divi's is a leading global player in specific APIs like Naproxen and Gabapentin, maintaining an established market position in the CRAMS segment.
Strategic Alliances
The company maintains long-term contracts and confidentiality agreements with major global innovator pharmaceutical companies for custom synthesis and CRAMS.
External Factors
Industry Trends
The pharmaceutical industry is evolving with a high focus on product quality, safety, and regulatory compliance. There is an increasing trend toward outsourcing to CRAMS providers like Divi's, which is positioning itself by expanding capacity and focusing on complex chemistry.
Competitive Landscape
The company competes with global and domestic API manufacturers. It stays competitive by optimizing processes and upgrading multi-purpose plant capacities to maintain a cost-competitive and fast delivery structure.
Competitive Moat
The moat is built on extensive promoter experience (30+ years), proven R&D capabilities, and long-standing relationships with global innovators. This is sustained by the high switching costs for customers in the Custom Synthesis segment due to regulatory filings and technical complexity.
Macro Economic Sensitivity
The company is sensitive to global trade patterns and geopolitical shifts. However, its 10.79% constant currency growth suggests resilience against minor macro fluctuations.
Consumer Behavior
Not applicable as the company is a B2B API and CRAMS provider.
Geopolitical Risks
Geopolitical developments are noted as factors affecting supply chains. The company's high exposure to US and Europe (74% of revenue) makes it vulnerable to trade policy changes in these regions.
Regulatory & Governance
Industry Regulations
The industry is highly regulated by authorities like the USFDA. Non-compliance can lead to import alerts, product recalls, and regulatory bans, which would severely impact the 90% export revenue base.
Environmental Compliance
Divi's invested in sustainability, reducing ~19,000 tCO2e GHG emissions and conserving ~130,300 KL of water in FY24. It also installed RO plants in 133 schools as part of its social progress initiatives.
Legal Contingencies
The company faces potential litigation risks common in the pharma industry related to product withdrawals or regulatory actions, though no specific high-value pending court cases were detailed in the provided text.
Risk Analysis
Key Uncertainties
Key risks include regulatory non-compliance (potential for import alerts), revenue concentration in top 5 products (risk if >60%), and significant forex volatility affecting the INR 2,006 Cr net asset exposure.
Geographic Concentration Risk
High geographic concentration with 74% of revenue derived from the US and Europe. Any regional regulatory shift or trade barrier in these markets would have a high impact on total income.
Third Party Dependencies
Dependency on global suppliers for 45% of raw material requirements, making the company vulnerable to international supply chain disruptions.
Technology Obsolescence Risk
The company mitigates technology risk through continuous R&D and upgrading multi-purpose manufacturing facilities to handle evolving complex chemistry requirements.
Credit & Counterparty Risk
The company maintains a high collection period to support client relationships, but liquidity remains comfortable with INR 4,229 Cr in cash and investments, mitigating counterparty credit risk.